MYGN vs NTRA
MYGN: Myriad Genetics is a molecular diagnostics and precision medicine company that develops genetic tests for cancer screening, therapy selection, prenatal health, and mental health to guide clinical decisions and improve patient outcomes. NTRA: Natera uses proprietary blood-based cell-free DNA technology to deliver personalized genetic diagnostics for oncology, prenatal screening, and organ transplant health.
Side-by-side fundamentals
| Metric | MYGN | NTRA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.66 | $264.22 | |
| Market cap as of 2026-07-23 | $547M | $37.9B | |
| PEG as of 2026-07-23 | -0.00 | -13.63 | NTRA lower |
| Net margin as of 2026-07-23 | -48.2% | -9.1% | NTRA higher |
| Gross margin as of 2026-07-23 | +70.0% | +65.1% | MYGN higher |
| Operating margin as of 2026-07-23 | -46.9% | -13.0% | NTRA higher |
| ROE as of 2026-07-23 | -109.1% | -15.1% | NTRA higher |
| ROA as of 2026-07-23 | -57.4% | -10.5% | NTRA higher |
| Debt / equity as of 2026-07-23 | 0.36 | 0.05 | NTRA lower |
| Revenue growth (YoY) as of 2026-07-23 | -0.3% | +36.6% | NTRA higher |
| Revenue CAGR (3y) SEC XBRL | +6.7% | +41.1% | NTRA higher |
| Beta as of 2026-07-23 | 1.62 | 1.54 | |
| 1-year return as of 2026-07-22 close | +23.3% | +88.8% | NTRA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.